<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458211</url>
  </required_header>
  <id_info>
    <org_study_id>BPCIRB 03-02</org_study_id>
    <nct_id>NCT00458211</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics</brief_title>
  <official_title>Evaluation of Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotic Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bronx Psychiatric Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Buffalo Psychiatric Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rochester Psychiatric Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bronx Psychiatric Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because ziprasidone has not been extensively studied and is not widely accepted in the
      severely mentally ill in State hospitals this study aims to demonstrate its effectiveness and
      relative lack of side effects. 75 patients with schizophrenia or schizoaffective disorder who
      need a change of medication because of ineffectiveness or side effects will be changed to
      ziprasidone and followed with detailed assessments for eight weeks.

      The hypothesis is that they will improve and have fewer side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ziprasidone has been found in studies and practice to be efficacious and tolerated well but
      has not been well studied or well accepted in the very severely ill in State Hospitals. This
      study aims to fill that gap by examining 75 patients with schizophrenia or schizoaffective
      disorder who require a change of medication because of poor response or unacceptable side
      effects.

      After signing consent and having a baseline assessment they will, if necessary, be reduced to
      one antipsychotic then started on ziprasidone, increasing to 160mg the second day. The one
      antipsychotic they had been on will be reduced over a week and stopped. The ziprasidone can
      be increased to 240mg after three weeks if necessary.

      The study will last eight weeks with efficacy assessed by Clinical Global Impressions (CGI),
      Positive and Negative Syndrome Scale (PANSS) every two weeks and Brief Assessment of
      Cognition, Calgary Depression Scale for Schizophrenia, Personal Evaluation of Transitions in
      Treatment and Medical Outcomes Study Cognitive Questions at the beginning and end. Side
      effects will be measured by movement disorder scales (Simpson-Angus scale for Parkinsonism
      (SANRS), Abnormal Involuntary Movement Scale (AIMS) and Barnes Akathisia Scale (BAS)), ECG
      and weight and blood metabolic measures.

      The hypothesis is that ziprasidone will be generally effective and that side effects
      especially metabolic indices will be reduced.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS) Measuring Symptoms of Schizophrenia</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Minimum score 32 (best) maximum 210 (worst)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Scores the Evaluator's Overall Impression of Severity (CGI-S) or Change (CGI-I) in Illness.</measure>
    <time_frame>8 weeks</time_frame>
    <description>CGI-S scores from 1 = normal to 7 = most extremely ill</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>8 weeks</time_frame>
    <description>Amount of glucose in the blood in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Involuntary Movement Scale (AIMS) Measures Tardive Dyskinesia</measure>
    <time_frame>8 weeks</time_frame>
    <description>Scores 0 (none) to 4 (severe) choreo-athetoid and dystonic movements of seven parts of the body with a maximum score 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simpson-Angus Scale Measures Drug Induced Parkinsonism</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measures 10 signs, (not all of which are now considered Parkinsonism), minimum score 0 (no Parkinsonism) maximum 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected QT Interval (QTc)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Time interval between Q and T waves on EKG corrected for pulse rate. Over 500 msec may be dangerous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Assessment of Cognition in Schizophrenia (BACS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Scores on the BACS scale, which measures cognition, were changed to Z-scores based on normal controls from Keefe (2008) A Z-score of zero would indicate cognition the same as the normal controls. Negative scores indicate cognition worse than the normal. Theoretically there are no maximum or minimum scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calgary Depression Scale for Schizophrenia</measure>
    <time_frame>8 weeks</time_frame>
    <description>Score on scale, from 0 to 27, above 6 considered indicative of depression, higher scores mean worse outcome,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Evaluation of Transitions in Treatment Scale (PETiTP</measure>
    <time_frame>8 weeks</time_frame>
    <description>PETiT is a 30 item self administered scale measuring response to and tolerability and adherence to antipsychotic medication in people with schizophrenia. The range is 30 to 100. Higher scores are better. Although different features are assessed there is a single total score - no subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Study Cognitive Functioning Scale (MOS-COG)</measure>
    <time_frame>8 weeks</time_frame>
    <description>MOS-COG measures day to day problems in six aspects of cognitive functioning. The scores are converted to 0-100 and so can range from 0 to 100 with 100 being the best. Population means are 70 to 80.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barnes Akathisia Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Barnes Akathisia Scale measures akathisia: a score of zero is none (good) maximum score is 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>8 weeks</time_frame>
    <description>Lab measure of glycated hemoglobin indicative of blood glucose over the last three months. At that time in the US measured as a percentage (of glucose attached to hemoglobin). No maximum or minimum but over 6.5% is generally considered indicative of diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Level</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measure of the amount of insulin in the blood, in uIU/ml. No minimum or maximum but fasting levels are usually below 25 uIU/ml. After a dose of glucose they may be 30 to 230 uIU/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antipsychotic Medication Costs</measure>
    <time_frame>8 weeks</time_frame>
    <description>No data were collected because it turned out we had no way of measuring the costs.
No subjects were analysed by costs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label change to ziprasidone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziprasidone</intervention_name>
    <description>Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia or schizoaffective

          -  Capacity to give consent

          -  Stable, on the same medication for a month but only partial response or with
             unacceptable side effects 18-65 years of age

        Exclusion Criteria:

          -  Repeated non-compliance

          -  Current depot medication

          -  Active medical conditions

          -  QTc &gt;500msec

          -  Previous non-response

          -  Previous treatment with ziprasidone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Bark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bronx Psychiatric Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Grace, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buffalo Psychiatric Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Schwarzkopf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester Psychiatric Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bronx Psychiatric Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo Psychiatric Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2007</study_first_submitted>
  <study_first_submitted_qc>April 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2007</study_first_posted>
  <results_first_submitted>April 25, 2012</results_first_submitted>
  <results_first_submitted_qc>March 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2013</results_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bronx Psychiatric Center</investigator_affiliation>
    <investigator_full_name>Nigel Bark MD</investigator_full_name>
    <investigator_title>Director of Scizophrenia Research</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Ziprasidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>40 subjects from three State Hospitals were recruited and participated between 2005 and 2008: four in-patients from Rochester Psychiatric Center, 17 out-patients from Buffalo Psychiatric Center and 19 in-patients from Bronx Psychiatric Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>Open label change to ziprasidone up to 120mg twice a day with meals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24">12 early termination 2 protocol violation 2 ( from Rochester) withdrawn from further analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The four Rochester subjects were dropped. The 17 Buffalo subjects were all out patients and 20 years older than the 19 Bronx subjects who were all in-patients. Buffalo subjects were 88% white (Bronx 5%), 12% African American (Bronx 39%), 0% Hispanic (Bronx 50%), 24% with Substance abuse (Bronx 68%)</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Open label change to ziprasidone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Positive and Negative Syndrome Scale (PANSS) Measuring Symptoms of Schizophrenia</title>
        <description>Minimum score 32 (best) maximum 210 (worst)</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>The four Rochester subjects were dropped as Rochester could not continue the study.19 Bronx and 17 Buffalo subjects were analyzed separately because they were so different(see baseline characteristics)</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Syndrome Scale (PANSS) Measuring Symptoms of Schizophrenia</title>
          <description>Minimum score 32 (best) maximum 210 (worst)</description>
          <population>The four Rochester subjects were dropped as Rochester could not continue the study.19 Bronx and 17 Buffalo subjects were analyzed separately because they were so different(see baseline characteristics)</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression (CGI) Scores the Evaluator's Overall Impression of Severity (CGI-S) or Change (CGI-I) in Illness.</title>
        <description>CGI-S scores from 1 = normal to 7 = most extremely ill</description>
        <time_frame>8 weeks</time_frame>
        <population>17 Buffalo subjects and 19 Bronx subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression (CGI) Scores the Evaluator's Overall Impression of Severity (CGI-S) or Change (CGI-I) in Illness.</title>
          <description>CGI-S scores from 1 = normal to 7 = most extremely ill</description>
          <population>17 Buffalo subjects and 19 Bronx subjects</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <time_frame>8 weeks</time_frame>
        <population>Same as PANNS above</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <population>Same as PANNS above</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Glucose</title>
        <description>Amount of glucose in the blood in mg/dl</description>
        <time_frame>8 weeks</time_frame>
        <population>See PANSS above</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose</title>
          <description>Amount of glucose in the blood in mg/dl</description>
          <population>See PANSS above</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cholesterol</title>
        <time_frame>8 weeks</time_frame>
        <population>See PANSS above</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol</title>
          <population>See PANSS above</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Involuntary Movement Scale (AIMS) Measures Tardive Dyskinesia</title>
        <description>Scores 0 (none) to 4 (severe) choreo-athetoid and dystonic movements of seven parts of the body with a maximum score 28</description>
        <time_frame>8 weeks</time_frame>
        <population>17 Buffalo subjects and 19 Bronx subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>All subjects, 17 at Buffalo and 19 at Bronx were given Ziprasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Involuntary Movement Scale (AIMS) Measures Tardive Dyskinesia</title>
          <description>Scores 0 (none) to 4 (severe) choreo-athetoid and dystonic movements of seven parts of the body with a maximum score 28</description>
          <population>17 Buffalo subjects and 19 Bronx subjects</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simpson-Angus Scale Measures Drug Induced Parkinsonism</title>
        <description>Measures 10 signs, (not all of which are now considered Parkinsonism), minimum score 0 (no Parkinsonism) maximum 40.</description>
        <time_frame>8 weeks</time_frame>
        <population>see PANNS above</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone</description>
          </group>
        </group_list>
        <measure>
          <title>Simpson-Angus Scale Measures Drug Induced Parkinsonism</title>
          <description>Measures 10 signs, (not all of which are now considered Parkinsonism), minimum score 0 (no Parkinsonism) maximum 40.</description>
          <population>see PANNS above</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corrected QT Interval (QTc)</title>
        <description>Time interval between Q and T waves on EKG corrected for pulse rate. Over 500 msec may be dangerous</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone</description>
          </group>
        </group_list>
        <measure>
          <title>Corrected QT Interval (QTc)</title>
          <description>Time interval between Q and T waves on EKG corrected for pulse rate. Over 500 msec may be dangerous</description>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baeline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Assessment of Cognition in Schizophrenia (BACS)</title>
        <description>Scores on the BACS scale, which measures cognition, were changed to Z-scores based on normal controls from Keefe (2008) A Z-score of zero would indicate cognition the same as the normal controls. Negative scores indicate cognition worse than the normal. Theoretically there are no maximum or minimum scores.</description>
        <time_frame>8 weeks</time_frame>
        <population>The overall number of participants is made up of 17 at Buffalo and 19 in the Bronx</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone up to 120mg twice a day with meals, 17 at Buffalo, 19 at Bronx</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Assessment of Cognition in Schizophrenia (BACS)</title>
          <description>Scores on the BACS scale, which measures cognition, were changed to Z-scores based on normal controls from Keefe (2008) A Z-score of zero would indicate cognition the same as the normal controls. Negative scores indicate cognition worse than the normal. Theoretically there are no maximum or minimum scores.</description>
          <population>The overall number of participants is made up of 17 at Buffalo and 19 in the Bronx</population>
          <units>Z-score from score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Calgary Depression Scale for Schizophrenia</title>
        <description>Score on scale, from 0 to 27, above 6 considered indicative of depression, higher scores mean worse outcome,</description>
        <time_frame>8 weeks</time_frame>
        <population>19 at Bronx, 17 at Buffalo</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone up to 120mg twice a day with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Calgary Depression Scale for Schizophrenia</title>
          <description>Score on scale, from 0 to 27, above 6 considered indicative of depression, higher scores mean worse outcome,</description>
          <population>19 at Bronx, 17 at Buffalo</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Evaluation of Transitions in Treatment Scale (PETiTP</title>
        <description>PETiT is a 30 item self administered scale measuring response to and tolerability and adherence to antipsychotic medication in people with schizophrenia. The range is 30 to 100. Higher scores are better. Although different features are assessed there is a single total score - no subscales.</description>
        <time_frame>8 weeks</time_frame>
        <population>36 subjects entered, 17 at Buffalo and 19 in the Bronx</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>All subjects, 17 at Buffalo and 19 at Bronx were given Ziprasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Evaluation of Transitions in Treatment Scale (PETiTP</title>
          <description>PETiT is a 30 item self administered scale measuring response to and tolerability and adherence to antipsychotic medication in people with schizophrenia. The range is 30 to 100. Higher scores are better. Although different features are assessed there is a single total score - no subscales.</description>
          <population>36 subjects entered, 17 at Buffalo and 19 in the Bronx</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcomes Study Cognitive Functioning Scale (MOS-COG)</title>
        <description>MOS-COG measures day to day problems in six aspects of cognitive functioning. The scores are converted to 0-100 and so can range from 0 to 100 with 100 being the best. Population means are 70 to 80.</description>
        <time_frame>8 weeks</time_frame>
        <population>All subjects, 17 at Buffalo, 19 in the Bronx</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone up to 120mg twice a day with meals, 17 at Buffalo, 19 at Bronx</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcomes Study Cognitive Functioning Scale (MOS-COG)</title>
          <description>MOS-COG measures day to day problems in six aspects of cognitive functioning. The scores are converted to 0-100 and so can range from 0 to 100 with 100 being the best. Population means are 70 to 80.</description>
          <population>All subjects, 17 at Buffalo, 19 in the Bronx</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Barnes Akathisia Scale</title>
        <description>Barnes Akathisia Scale measures akathisia: a score of zero is none (good) maximum score is 12</description>
        <time_frame>8 weeks</time_frame>
        <population>All subjects entered, 17 at Buffalo, 19 at Bronx</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>All subjects, 17 at Buffalo and 19 at Bronx were given Ziprasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Barnes Akathisia Scale</title>
          <description>Barnes Akathisia Scale measures akathisia: a score of zero is none (good) maximum score is 12</description>
          <population>All subjects entered, 17 at Buffalo, 19 at Bronx</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c</title>
        <description>Lab measure of glycated hemoglobin indicative of blood glucose over the last three months. At that time in the US measured as a percentage (of glucose attached to hemoglobin). No maximum or minimum but over 6.5% is generally considered indicative of diabetes.</description>
        <time_frame>8 weeks</time_frame>
        <population>All subjects entered, 19 in the Bronx, 17 at Buffalo</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone up to 120mg twice a day with meals</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c</title>
          <description>Lab measure of glycated hemoglobin indicative of blood glucose over the last three months. At that time in the US measured as a percentage (of glucose attached to hemoglobin). No maximum or minimum but over 6.5% is generally considered indicative of diabetes.</description>
          <population>All subjects entered, 19 in the Bronx, 17 at Buffalo</population>
          <units>HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Level</title>
        <description>Measure of the amount of insulin in the blood, in uIU/ml. No minimum or maximum but fasting levels are usually below 25 uIU/ml. After a dose of glucose they may be 30 to 230 uIU/ml.</description>
        <time_frame>8 weeks</time_frame>
        <population>All subjects entered, 17 at Buffalo, 19 at Bronx</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone up to 120mg twice a day with meals, 17 at Buffalo, 19 at Bronx</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Level</title>
          <description>Measure of the amount of insulin in the blood, in uIU/ml. No minimum or maximum but fasting levels are usually below 25 uIU/ml. After a dose of glucose they may be 30 to 230 uIU/ml.</description>
          <population>All subjects entered, 17 at Buffalo, 19 at Bronx</population>
          <units>uIU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronx baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronx end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Buffalo end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antipsychotic Medication Costs</title>
        <description>No data were collected because it turned out we had no way of measuring the costs.
No subjects were analysed by costs</description>
        <time_frame>8 weeks</time_frame>
        <population>We had no measure of costs, no data were collected</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open label change to ziprasidone
ziprasidone: Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Antipsychotic Medication Costs</title>
          <description>No data were collected because it turned out we had no way of measuring the costs.
No subjects were analysed by costs</description>
          <population>We had no measure of costs, no data were collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the time subjects were in the study - screening till 8 weeks on ziprasidone.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>Open label change to ziprasidone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Relapse of out patient required admission</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nigel Bark MD</name_or_title>
      <organization>Bronx Psychiatric Center</organization>
      <phone>718 862 5429</phone>
      <email>Nigel.Bark@omh.ny.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

